Parsippany, New Jersey. Edenbridge Pharmaceuticals, LLC announces that it has received final approval from the U.S. Food and Drug Administration on its Abbreviated New Drug Application for Diltiazem Hydrochloride Tablets, USP (30 mg, 60 mg, 90 mg, and 120 mg), a generic version of Cardizem®* tablets (30 mg, 60 mg, 90 mg, and 120 mg). Edenbridge intends to begin shipping this newly approved product shortly. For more information please contact the Company directly at info@dexcelpharmausa.com.
Diltiazem Hydrochloride Tablets, USP Approval
Specialty Products
To learn more about our specialty products, vigabatrin and Yargesa®, and how you may be able to save, please visit the Products page or navigate to a product-specific page.
Specialty Products
To learn more about our specialty products, vigabatrin and Yargesa®, and how you may be able to save, please visit the Products page or navigate to a product-specific page.